Go Pro
→ NASA's ISS Replacement Could Go to This Tiny Space Firm (From Behind the Markets) (Ad)tc pixel
NASDAQ:IMA

ImageneBio Q1 2025 Earnings Report

ImageneBio logo
$4.87 +0.02 (+0.37%)
Closing price 09/23/2026 03:58 PM Eastern
Extended Trading
$4.86 -0.01 (-0.27%)
As of 09/23/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

ImageneBio EPS Results

Actual EPS
-$2.16
Consensus EPS
-$2.52
Beat/Miss
Beat by +$0.36
One Year Ago EPS
N/A

ImageneBio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ImageneBio Announcement Details

Quarter
Q1 2025
Date
5/8/2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

ImageneBio's Q1 2025 Quarterly reportQuarterly report
(10-Q)

ImageneBio Earnings Headlines

ImageneBio, Inc. (NASDAQ:IMA) Receives $29.00 Average PT from Analysts
September 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31033813
ImageneBio Corporate Event Calendar | NASDAQ:IMA
September 13, 2026  |  benzinga.comhttps://www.benzinga.com/quote/IMA/events
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to build its replacement is reportedly headed to a tiny firm a fraction of SpaceX's size, one NASA has quietly funded for five years. History shows these NASA announcements can move fast: Intuitive Machines jumped 66% in a day, Momentus soared 155%, and Sidus Space climbed 180% after landing subcontractor roles.tc pixel
 |  Behind the Markets (Ad)
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
September 8, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/imagenebio-to-participate-in-h-c-wainwright-28th-annual-global-investment-conference-in-new-york-1036530172
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3358135/0/en/imagenebio-to-participate-in-h-c-wainwright-28th-annual-global-investment-conference-in-new-york.html
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/imagenebio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-1036468494
See More ImageneBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImageneBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImageneBio and other key companies, straight to your email.

About ImageneBio

ImageneBio (NASDAQ:IMA) is a biotechnology company focused on precision oncology and the development of blood-based tools for cancer research and clinical care. The company’s work centers on analyzing tumor-derived genetic material found in blood, with the goal of providing noninvasive information about a patient’s cancer.

Its technology is designed to support tumor profiling, biomarker identification, and the monitoring of disease over time. By combining molecular analysis with computational methods, ImageneBio aims to help physicians and researchers characterize tumors, identify potentially relevant treatment options, and evaluate changes in tumor biology.

Publicly available information about ImageneBio’s commercial portfolio, geographic operations, and leadership is limited. The company is associated with the ticker symbol IMA on the Nasdaq Stock Market.

View ImageneBio Profile
Earnings Tools